Fig. 8
Drug sensitivity analysis of PDGFD in AML. (A) ABT.263: Inhibitor of the Bcl-2 protein family, acting on Bcl-xL, Bcl-2 and Bcl-w; (B) AMG.706: ATP-competitive inhibitor of Vascular endothelial growth factor receptor (VEGFR)1/2/3; (C) Axitinib: Inhibitor of VEGFR; (D) AZD.0530: inhibitor of the Src family; (E) AZD7762: ATP-competitive checkpoint kinase (Chk) inhibitor; (F) Bicalutamide: non-steroidal androgen receptor (AR) antagonist; (G) BX.795: Inhibitor of PDK1; (H) GDC0941: Inhibitor of PI3Kα/δ; (I) Imatinib: Inhibitor of the tyrosine kinase; (J) KU.55,933: Inhibitor of the ATM; (K) Lenalidomide: Immunomodulator; (L) LFM.A13: Inhibitor of the BTK, JAK2, PLK; (M) NU.7441: Inhibitor of the DNA-PK; (N) NVP.TAE684: Inhibitor of the ALK; (O) OSI.906: Inhibitor of the insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF-1R) kinases; (P) PD.0332991: Inhibitor of the cyclin D kinase 4/6; (Q) PF.02341066: Inhibitor of the ATP-competitive ALK and c-Met; (R) PF.562,271: ATP-competitive and reversible FAK and Pyk2 kinase inhibitor; (S) PHA.665,752: ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase; (T) PLX4720: Inhibitor of B-Raf-V600E; (U) SB.216,763: Inhibitor of the ATP-competitive GSK-3; (V) Sunitinib: Inhibitor of the tyrosine kinase; (W) WO2009093972: A potent HSP90 inhibitor; * P < 0.05; ** P < 0.01; ***P < 0.001; ns, non-significant.
